A Look At Biotec Pharmacon ASA’s (OB:BIOTEC) Exceptional Fundamentals - Simply Wall St  February 26, 2019

https://simplywall.st/stocks/no/pharmaceuticals-biotech/ob-biotec/biotec-pharmacon-shares/news/a-look-at-biotec-pharmacon-asas-obbiotec-exceptional-fundamentals/?fbclid=IwAR39j4be2R6PGQ0QxWUffsoOZHTQoyOszJfSrUSeRQ-CIha_UG-nQpdZzo4

Building up an investment case requires looking at a stock holistically. Today I’ve chosen to put the spotlight on Biotec Pharmacon ASA (OB:BIOTEC) due to its excellent fundamentals in more than one area. BIOTEC is a company with impressive financial health as well as a buoyant growth outlook. Below, I’ve touched on some key aspects you should know on a high level. For those interested in understanding where the figures come from and want to see the analysis, take a look at the report on Biotec Pharmacon here.

Flawless balance sheet with exceptional growth potential

One reason why investors may be attracted to BIOTEC is its explosive triple-digit earnings growth potential in the near future, underlying the notable 42% return on equity over the next few years leading up to 2022. BIOTEC is financially robust, with ample cash on hand and short-term investments to meet upcoming liabilities. This implies that BIOTEC manages its cash and cost levels well, which is a crucial insight into the health of the company. Looking at BIOTEC’s capital structure, the company has no debt on its balance sheet. It has only utilized funding from its equity capital to run the business, which is typically normal for a small-cap company. Therefore the company has plenty of headroom to grow, and the ability to raise debt should it need to in the future.